You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

28 Results
Regimen
Intent: Adjuvant
Funding:
ODB - General Benefit
    anastrozole
Apr 2024
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Adjuvant
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Pancreas
Intent: Adjuvant, Palliative
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Pancreas
Intent: Adjuvant, Palliative
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Adjuvant, Adjuvant
Nov 2017
Regimen
Cancer Type:
Gastrointestinal, 
Anus
Intent: Adjuvant
Apr 2023
Regimen
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Jan 2024
Regimen
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Feb 2022
Regimen
Intent: Neoadjuvant, Adjuvant
Jun 2020
Regimen
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Feb 2022
Regimen
Regimen

Pages